Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009.

Slides:

Advertisements

Similar presentations

Breast Cancer Patient Issues in Family Practice: An Interactive Session.

Advertisements

Mammary ductal carcinoma

Evidence for adjuvant radiation therapy benefiting breast cancer patients with 1 to 3 positive lymph nodes treated with a modified radical mastectomy and.

Baptist Health System General Surgery Residency Program

Ismail Jatoi, MD, PhD, FACS Dale H. Dorn Chair in Surgery Professor and Chief, Division of Surgical Oncology University of Texas Health Science Center.

Pimp Session: Breast By James Lee, MD.

Advances and Emerging Therapy for Lung Cancer

Breast Cancer. Introduction Most common female cancer Accounts for 32% of all female cancer 211,300 new cases yearly and rising 40,000 deaths yearly.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Breast Cancer in Pregnancy

Modified Megestrol The Clinical Trials by : Carolina R. Akib

The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

Breast Reconstruction: Outcomes Analysis Michael J Bass, MD, JD Michael J Bass Plastic Surgery, PLLC.

Breast Cancer Tumor Board Chair Harold Burstein, MD, PhD Faculty Jennifer Bellon, MD Mehra Golshan, MD.

Oncology Assessment and Management of Patients With Cancer Breast Prepared by Dr. Iman Abdullah.

Sentinel Lymph Node Dissection (SND)

What is cancer? A cancer is a malignant tumor, which are cells that multiply out of control, destroying healthy tissues (Dictionary)

Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery

AJCC TNM Staging 7th Edition Breast Case #3

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.

Radiotherapy in Carcinoma of the Breast Patrick S Swift, MD Director, Radiation Oncology Alta Bates Comprehensive Cancer Center Berkeley, CA.

Hot topics in breast radiotherapy Mark Beresford.

Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

Elshami M.Elamin, MD Medical Oncologist Central Care Cancer Center Wichita, KS, USA

Nurse Navigators and the Cancer Institute Yousuf A. Gaffar, MD Hematology / Medical Oncology The Cancer Institute University of Maryland St. Joseph Medical.

Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.

Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.

 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.

Breast Carcinoma. Anatomy Epidemiology: 10% 17.1/10 28/10 46/ m world wide 6% develop cancer of the breast in their lifetime. 50,000 to 70,000.

Breast Cancer Methods for Early Detection. Breast Cancer What It Is Methods of Early Detection Risk Factors.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

NYU Medical Grand Rounds Clinical Vignette Daniel P. Eiras, MD, MPH PGY2 December 1, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2013 – December 31, 2013 Compiled by Uzma Nazim, M.D.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.

NYU Medical Grand Rounds Clinical Vignette Denise Pate MD, PGY-2 January 27, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

MBCG Project Primary Results MEDICALSURVEYS-17 RESEARCH GROUP IN COLLABORATION WITH THE EASO.

Recent and evolving trends in breast and colon cancer by Jeff Kolbasnik.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2014 – December 31, 2014 Compiled by L.Day, RN BSN CCM CCRP OCN 1.

Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.

The breast disease. Benign disease Present as; 1. Pain 2. Mass 3. Discharge 4. Abnormal appearance.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2011 – December 31, 2011 Compiled by Lynn Day, RN BSN CCM CCRP.

2015 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2012 – December 31, 2012 Compiled by Uzma Nazim, M.D.

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2010 – December 31, 2010 Compiled by Lynn Day, RN BSN CCM CCRP.

Extranodal Extension on Sentinel Lymph Node Dissection: Why Should We Treat It Differently? Audrey Choi MD, Matthew Surrusco MD, Samuel Rodriguez MD, Khaled.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Basis and Outcome of Axillary Dissection for Node Negative Axilla Gurpreet Singh Dept. Of Surgery P.G.I.M.E.R. These Power Point presentations are free.

SLNB Scenario Group Discussion Presented at: The Sentinel Lymph Node Biopsy Surgery Refresher Course October 29, 2010.

Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in

Annals of Oncology 24: 2206–2223, 2013 R3 조영학

BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Presented at the NAACCR Annual Conference Quebec City June 22, 2010.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

Advanced loco regional Regional breast cancer

Oncology Assessment and Management of Patients With Cancer Breast

BREAST CANCER ONCOLOGY NAVIGATION SERVICE

Marcelo Calil Instituto Brasileiro de Controle do Câncer

Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT

徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2

Protocol Summary National Wilms Tumor Study Group (NWTS)

Presentation transcript:

Quality Assurance Report TTUHSC Breast Center of Excellence January 1, 2009 – December 31, 2009

Stage Distribution Total Number of Patients = 106 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun4 (8.5%) 13 (27.6%) 20 (42.5%) 8 (17.0%) 2 (4.25%) -47 (100%) Jul - Dec8 (16.5%) 22 (37.2%) 20 (33.8%) 6 (10.1%) -3 (5.0%) 59 (100%) Jan-Dec12 (11.3%) 35 (33.0%) 40 (37.7%) 14 (13.2%) 2 (1.8%) 3 (2.8%) 106 (100%)

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Preoperative Core 4 (8.5%) 13 (27.6%) 20 (42.5%) 8 (17.0%) 2 (4.25%) -47 (100%) Jul – Dec Preoperative Core 8 (16.5%) 22 (37.2%) 20 (33.8%) 6 (10.1%) -3 (5.0%) 59 (100%) Jan-Dec Preoperative Core 12 (11.3%) 35 (33.0%) 40 (37.7%) 14 (13.2%) 2 (1.8%) 3 (2.8%) 106 (100%) Mode of Diagnosis Total Number of Patients = % of patients had diagnosis established on preoperative core needle biopsy

Tumor Board Discussion Total Number of Patients = 106 Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Discussed 3/4 (75.0%) 12/13 (92.3%) 15/20 (75.0%) 7/8 (87.5%) 2/2 (100%) -39/47 (82.9%) Jul – Dec Discussed 5/8 (62.5%) 13/22 (59.0%) 16/20 (80.0%) 4/6 (66.6%) -2/3 (66.6%) 40/59 (67.8%) Jan-Dec Discussed 8/12 (66.6%) 25/35 (71.4%) 31/40 (77.5) 11/14 (78.5%) 2/2 (100%) 2/3 (66.6%) 79/106 (74.5%) 74.5% of patients were discussed prospectively in the multidisciplinary tumor conference

Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun MDC seen 2/4 (50.0%) 8/13 (61.4%) 12/20 (60.0%) 7/8 (87.5%) 1/2 (50.0%) -30/47 (63.8%) Jul – Dec MDC seen 4/8 (50.0%) 15/22 (68.1%) 14/20 (70.0%) 6/6 (100%) -2/3 (66.6%) 41/59 (69.4%) Jan-Dec MDC seen 8/12 (66.6%) 23/35 (65.7%) 26/40 (65.0%) 13/14 (92.8%) 1/2 (100%) 2/3 (66.6%) 71/106 (66.9%) Multidisciplinary Assessment (Surgical, Medical and Radiation Oncologist) Total Number of Patients = 106 Exceptions35/106 (33.0%) No radiation oncology evaluation (mast./ high-risk)31/35 (88.5%) No documentation in the chart2/35 (5.7%) Patient non-compliance2/35 (5.7%)

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Assigned 3/4 (75.0%) 12/13 (92.3%) 20/20 (100%) 8/8 (100%) 2/2 (100%) -45/47 (95.7%) Jul – Dec Assigned 6/8 (75.0%) 20/22 (90.9%) 19/20 (95.0%) 6/6 (100%) -3/3 (100%) 54/59 (91.5%) Jan-Dec Assigned 9/12 (75.0%) 32/35 (91.4%) 39/40 (97.5%) 14/14 (100%) 2/2 (100%) 3/3 (100%) 99/106 (93.3%) Nurse Navigation Total Number of Patients = 106 Exceptions7/106 (6.6%) Lateral entry into the system7/7 (100%)* * modifications made to ensure assignment of a nurse navigator for every patient

Time FrameStage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 2/4 (50.0%) 13/13 (100%) 20/20 (100%) 8/8 (100%) 1/2 (50.0%) -44/47 (93.6%) Jul – Dec Yes 2/8 (25.0%) 22/22 (100%) 20/20 (100%) 6/6 (100%) -1/2 (33.3%) 51/59 (86.4) Jan-Dec Yes 4/12 (33.3%) 35/35 (100%) 40/40 (100%) 14/14 (100%) 1/2 (50.0%) 1/3 (33.3%) 95/106 (89.6%) CAP Compliance Total Number of Patients = 106 Exceptions11/106 (10.3%) Progesterone receptor not reported8/11 (72.7%) Final surgery not done yet (neoadjuvant)3/11 (27.2%)

Axillary Staging Total Number of Patients = 106 Total Number of Patients with Invasive Cancer = 94 Number node positive patients on needle biopsy16/94 (17.0%) Number of patients eligible for SLNB78/94 (82.9%) – Number of patients with SLNB72/78 (92.3%) Exceptions6/78 (7.6%) Determined low risk (unlikely to change treatment plan)5/6 (83.3%) Stage IV disease documented1/6 (16.6%)

Axillary Dissection Total Number of Patients = 106 Total Number of Patients with Invasive Cancer = 94 Number of Patients with node positive disease42/94 (44.6%) Number of patients eligible for ALND42 – Number of patients with ALND28/42 (66.6%) Exceptions14/42 (33.3%) Low risk for non-SLN mets. on MSKCC nomogram13/14 (92.8%) Patient refused completion ALND1/14 (7.1)

Time Frame Stage 0Stage IStage IIStage IIIStage IVStage Unassigned Total Jan – Jun Yes 2/4 (50.0%) 11/13 (84.6%) 13/20 (65.0%) 4/8 (50.0%) 2/2 (100%) -30/47 (63.8%) Jul – Dec Yes 4/8 (50.0%) 15/22 (68.1%) 13/20 (65.0%) 1/6 (16.6%) -1/3 (33.3%) 34/59 (57.6%) Jan-Dec Yes 6/12 (50.0%) 26/35 (74.2%) 26/40 (65%) 5/14 (35.7%) 2/2 (100%) 1/3 (33.3%) 64/106 (60.3%) Breast Conservation Total Number of Patients = 106 Number of early stage patients (0,I and II) with breast conservation58/87 (66.6%)

Post-lumpectomy Radiation Total Number of Patients = 106 Number of patients with lumpectomy64/106 (60.3%) Number of patients eligible for Radiation64 – Number of patients radiated48/64 (75%) Exceptions16/64 (25%) Low risk malignancy age group 75 – 93 years16/16 (100%) severe co morbidities Number of patients radiated within 12 months48/48 (100%)

Post-Mastectomy Radiation Total Number of Patients = 106 Number of patients with mastectomy39/106 (36.7%) Number eligible for radiation (>T3 or >N2)10/39 (25.6%) – Number of patients radiated10/10 (100%) Exceptions0 (none) Number of patients radiated within 12 months10/10 (100%)

Systemic Chemotherapy - I Total Number of Patients = 106  ER negative patients with invasive cancer26/106 (24.5%) Number eligible for chemotherapy(exclude DCIS)22/26 (84.6%) – Number treated with chemotherapy20/22 (90.9%) Exceptions2/22 (9.2%) Patient refused (1 stage II, 1 stage III)2/2 (100%)  Number with chemotherapy within 4 months19/20 (95.0%) Exceptions1/20 (0.05%) Patient non-compliance (stage II)1/1 (100%)

Systemic Chemotherapy - II Total Number of Patients = 106  ER positive patients with invasive cancer74/106 (69.8%) Number treated with chemotherapy26 /74 (35.1%)  Number with chemotherapy within 4 months23/26 (88.4%) Exceptions3/26 (11.5%) Patient non-compliance (stage II)1/3 (33.3%) Postop. wound complications (1 stage I, 1 stage II)2/3 (66.6%)

Systemic Endocrine Therapy Total Number of Patients = 106  Number of ER positive patients80/106 (75.4%) Number treated with endocrine therapy64 /80 (80.0%) Exceptions16/80 (20.0%) Determined risk > benefit2/16 (12.5%) No documentation in the chart1/16 (6.25%) Patient non-compliance13/16 (81.25%)  Number with endocrine therapy within 1 year64/64 (100%)

Rehabilitation Total Number of Patients = 106 Number enrolled in CPRP (PT/OT)13/106 (12.25%) Number enrolled in CPRP (Psycho-oncology)0 Exceptions93/106 (87.7%) Services were available but structured program is recently put in place, whereby every patient gets a baseline arm girth and shoulder range of motion documented; prospective data is maintained with a pre-designed schedule.

Genetic Counseling Total Number of Patients = 106 Number of patients with family history or < 45 years49/106 (46.2%) Number received genetic counseling16/49 (32.6%) – Number tested6/33 (18.1%) Positive2/6 (33.3%) Negative4/6 (66.6%) – Number refused testing10 (20.4%) Exceptions33/49 (67.3%) Did not meet NCCN criteria29/33 (87.8%) No documentation in the chart2/33 (6.0%) patient non-compliance2/33 (6.0%)

Time Frame Trial / StudyEligible N (%) Participation N (%) Jan – Jun B-SMART-- SPOC-- SWOG S03072 (4.26%) Total 2 (4.26%) Jul - Dec (1.6%) B-SMART7 (11.8%) SPOC1 (1.6%) SWOG S03075 (8.4%)4 (6.7%) Total 14 (23.7%)13 (22.0%) Trial Participation Total Number of Patients = 106 Total Number of patients enrolled in trials in /106 (14.1%)